28th National Clinical Education Symposium Presentation Abstracts

Actions for Presentation

Download PDF Back to list

Other presentations

OP-09 The relationship between mental symptoms and body perception and selfesteem in patients wıth nasal septal deviatıon - Page 69
Ömer Naim Sayer, , Zeynep Soytürk, , Zerrin Ozergin Coskun, , Cicek Hocaoglu

OP-10 Investigation of Anhedonia, Anxiety Sensitivity, and Magnification of Bodily Sensations in Patients with Benign Paroxysmal Positional Vertigo - Page 71
Merve Çetin Sayer, , Zerrin Ozergin Coskun, , Cicek Hocaoglu

OP-11 Relationship between social media addiction, impulsivity, emotion regulation and cyberbullying among medical students - Page 73
Beyza Yıldırım, Fatih Ekici

OP-12 Efficacy of rTMS Treatment in Treatment-Resistant Major Depressive Disorder: The Role of Sociodemographic Characteristics and Duration of Illness on Treatment Response - Page 75
Erşad Yasin Yıldız, Pelin Goksel, Gökçe Çamoğlu

OP-13 Retrospective Analysis of the Effect of Sociodemographic Factors and Disease Duration on Yale-Brown Scale Scores in Patients with Treatment-Resistant Obsessive-Compulsive Disorder Who Had Transcranial Magnetic Stimulation at the Psychiatry Clinic - Page 76
FERDANUR Yolcu Çiftlik, Pelin Göksel, Gökçe Çamoğlu

OP-14 Sexual Satisfaction, Guilt, and Shame in Women with Obsessive–Compulsive Disorder and Generalized Anxiety Disorder - Page 77
Selin Karakaya, , Ezgi Sıla Ahi Üstün, , Büşra Söylemez Karakuş, , Nurdan Özder, , İrem Tanrıkulu, , Meram Can Saka

20 APRIL 2026, MONDAY
08:45 - 10:00 OP-08 Metabolic Syndrome Shows an Independent Association with Comorbid Major Depressive Disorder in Schizophrenia Remission: A Cross-Sectional Study

OP-08 Metabolic Syndrome Shows an Independent Association with Comorbid Major Depressive Disorder in Schizophrenia Remission: A Cross-Sectional Study

Mehmet Avan1, Hayriye Dilek Hamurcu1, Begüm Pekiyi Avan1, Ali Çayköylü2

1. Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Psychiatry, Ankara
2. Ankara Yıldırım Beyazıt University, Faculty of Medicine, Department of Psychiatry, Ankara; Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Psychiatry, Ankara

DOI: 10.5080/61upk.ozt427 Page 67

BACKGROUND AND AIM: Major depressive disorder (MDD) is common in schizophrenia. Metabolic syndrome (MetS) is also frequent, but its independent association with comorbid MDD is uncertain. We estimated comorbid MDD prevalence in remitted schizophrenia and tested whether MetS is independently associated with MDD.
METHODS: This cross-sectional study evaluated 218 individuals with DSM-5 schizophrenia (July 2022–July 2023). Remission required ?6 months of stability, PANSS item scores ?3 for P1, P2, P3, N1, N4, N6, G5, and G9, and no psychiatric hospitalization within the past year. MDD was defined as CDSS ?7 with DSM-5–based clinical confirmation in the same encounter by a psychiatrist; ambiguous cases were reviewed with a senior clinician and resolved by consensus. MetS was defined per NCEP ATP III (?3): waist circumference >102 cm (men) or >88 cm (women); triglycerides ?150 mg/dL; HDL
CONCLUSIONS: MDD is frequent in remitted schizophrenia and shows an independent association with MetS. Screening for depression and cardiometabolic risk is warranted; longitudinal studies should clarify temporality and mechanisms. Keywords: Schizophrenia, Major depressive disorder, Metabolic syndrome, Calgary Depression Scale, Cardiometabolic risk